Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Metabolic dysfunction-Associated Steatotic Liver Disease
Fatty Liver Disease (MASLD/MASH)
Here are a Few of Our Recent Blog Posts
Uncovering the Silent Epidemic of MASLD/MASH
A Call to Action: Why Radiologists Must Have a Seat at the Table
A Call to Action: Why Radiologists Must Have a Seat at the Table
Key Insights on Fatty Liver Disease (MASLD) and How You Can Help
We’re excited to share the full video of our recent presentation on fatty liver disease (MASLD) affecting over 25% of North Americans and even more globally. Dr. Alnoor Ramji shares a great overview of this serious and silent liver disease.
Many are unaware they have it, so raising awareness is crucial. Watch the video to learn more about this silent but impactful disease.
A Call to Action: Why Radiologists Must Have a Seat at the Table
A Call to Action: Why Radiologists Must Have a Seat at the Table
A Call to Action: Why Radiologists Must Have a Seat at the Table
Why Radiologists Matter
The importance of radiology in managing MASLD and MASH cannot be overstated. Non-invasive imaging techniques, such as MRI-PDFF (Proton Density Fat Fraction) and elastography, are crucial tools in assessing liver fat content and fibrosis levels—key indicators of disease progression. Dr. Sirlin highlighted the advancements in quantitative imaging, which allow for precise measurements of liver health without the need for biopsies.
MASLD and MASH Vancouver Community Event
A Call to Action: Why Radiologists Must Have a Seat at the Table
Liver Cancer: From MASLD to MASH to HCC: Why Early Detection is Crucial
This week we will begin to share presentations and some great questions and answers about MASLD and MASH from our Vancouver community event. For today, here is a quick wrap up chat about the event - a teaser for what we will post this week.
Key take-aways include:
1. Early Diagnosis is Crucial
2. Role of Advocacy Groups
3. Multidisciplinary Approach:
4. Advancements in Diagnostic Tools
5. Public Awareness and Stigma
Liver Cancer: From MASLD to MASH to HCC: Why Early Detection is Crucial
Liver Cancer: From MASLD to MASH to HCC: Why Early Detection is Crucial
Liver Cancer: From MASLD to MASH to HCC: Why Early Detection is Crucial
October is liver cancer awareness month around the world, and it is a perfect time to share today's blog fo some Saturday reading.
Why is early detection critical?
What is the spectrum of disease from MASLD to MASH to HCC?
Why is early case finding so important?
Can early detection prevent liver cancer?
Is it time to shift our thinking to cancer prevention?
Check out our blog today where we share our thoughts on this life saving topic.
Moving the Agenda Forward for MASLD/MASH and Metabolic Health
Liver Cancer: From MASLD to MASH to HCC: Why Early Detection is Crucial
Moving the Agenda Forward for MASLD/MASH and Metabolic Health
Inspired and influenced greatly by this week's United Nations General Assembly Side-Event in NYC, we created this blog that we hope will contribute to the global discussion and work already being done by experts like Jeffrey V. Lazarus from Barcelona Institute for Global health (ISGlobal) the CUNY Graduate School of Public Health Policy, and Economist Impact who hosted this valuable global representation of health experts.
How Aligned are FIB-4 and Fibroscan Assessments?
Liver Cancer: From MASLD to MASH to HCC: Why Early Detection is Crucial
Moving the Agenda Forward for MASLD/MASH and Metabolic Health
Madeleine Chang is a high school senior at Arnold O. Beckman High School in Orange County, California,. She has a strong interest in biology and medicine, and has (with her brother Devon Chang, also a high-school student) been working with Dr. Mazen Noureddin, MD, MHSc, Hepatologist from Houston Research Institute on MASLD research for the last two to three years. We used the words 'heart warming' because it is so great seeing people as young as high-school students passionately exploring science in an effort to help patients! Madeleine is the first author of this paper!
Monitoring Resmetirom in Patients with MASH/NASH
Video #4: What patients need to know about Fatty Liver Disease (MASLD and MASH)
Navigating Communication Challenges Between Patients and Physicians
Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to noncirrhotic Advanced Fibrosis
Let's take a moment and revisit this very recent paper by Mazen Noureddin, Michael R. Charlton, Stephen A. Harrison, Meena B. Bansal, Naim Alkhouri, Rohit Loomba, Arun J. Sanyal, Mary E. Rinella
Navigating Communication Challenges Between Patients and Physicians
Video #4: What patients need to know about Fatty Liver Disease (MASLD and MASH)
Navigating Communication Challenges Between Patients and Physicians
Effective communication between patients and physicians is fundamental to delivering high-quality healthcare. However, several inherent challenges can make these interactions less than optimal. Patients often enter the consultation room with a sense of apprehension, particularly when dealing with chronic conditions such as fatty liver disease, obesity, or type-2 diabetes. They may respect their doctors greatly but feel inhibited, nervous, and unsure about how to convey their concerns effectively.
Video #4: What patients need to know about Fatty Liver Disease (MASLD and MASH)
Video #4: What patients need to know about Fatty Liver Disease (MASLD and MASH)
Video #3: What are MASLD and MASH? Can they be prevented? Is treatment available?
Millions are affected by fatty liver disease, and raising awareness is crucial. Wendy Schaufert has dedicated 10 years to working with patients, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly NAFLD/NASH.
Video #3: What are MASLD and MASH? Can they be prevented? Is treatment available?
Video #1: Your Liver Your Health: Understanding MASLD, MASH, Diabetes and Your Metabolic Health with
Video #3: What are MASLD and MASH? Can they be prevented? Is treatment available?
Dr. Swain provides an in-depth explanation of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH), highlighting the importance of recognizing and addressing these conditions early.
Video #2: What do MASLD and MASH look like? What do they feel like?
Video #1: Your Liver Your Health: Understanding MASLD, MASH, Diabetes and Your Metabolic Health with
Video #1: Your Liver Your Health: Understanding MASLD, MASH, Diabetes and Your Metabolic Health with
Video #2: Check out the interest from the Calgary, AB community.
Liam Swain sharing the Madrigal Pharmaceuticals liver model on Global Fatty Liver Day.
Video #1: Your Liver Your Health: Understanding MASLD, MASH, Diabetes and Your Metabolic Health with
Video #1: Your Liver Your Health: Understanding MASLD, MASH, Diabetes and Your Metabolic Health with
Video #1: Your Liver Your Health: Understanding MASLD, MASH, Diabetes and Your Metabolic Health with
We had an incredible event on June 13, 2024, for Global Fatty Liver Day! It was a privilege to host such a knowledgeable and engaged community in Calgary. As the President and Founder of the Fatty Liver Alliance, I’m thrilled to share some highlights and key takeaways from our first presentation titled "Your Liver, Your Health: Understanding Metabolic Dysfunction."
Urgent Call to Action
Fatty Liver Alliance in the News
The Fatty Liver Alliance a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian regulators for approval of Rezdiffra (resmetirom), the company’s oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
https://liverdiseasenews.com/news/nonprofits-petition-aims-expedite-canadian-access-rezdiffra/
Canadians Deserve Equal Access to Life-Saving Liver Treatment - Sign the Petition Now!
Today, we're taking a crucial step forward in advocating for Canadians diagnosed with MASH (Metabolic dysfunction-Associated Steatohepatitis).
We've launched a petition asking Madrigal Pharmaceuticals to apply to Health Canada, so that Canadians can have access to Rezdiffra—a vital treatment for MASH.
Your support is essential! Please take a moment to sign our petition and share this with your network. Together, we can make a difference!
🔗 Sign the Petition Here: https://globalliver.salsalabs.org/petitionrezdiffracanada
🔗 Read Our Media Release: Urgent Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment--Sign the Petition Now!
Thank you for standing with us in this important cause.
Our Team
Our History
Our History
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our History
Our History
Our History
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 11.64M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
Our Mission
Our History
Our Mission
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by advocating for access to approved treatments and care.
I want to get involved!
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
Collaboration: Global Liver Institute-Liver Action Network
